Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Fineline Cube Mar 13, 2026
Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration

Fineline Cube Jul 11, 2023

China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU)...

Company Deals

BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development

Fineline Cube Jul 11, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing...

Company Deals

Bayer and Peking University Enter Fourth Phase of Partnership to Advance Drug Discovery

Fineline Cube Jul 11, 2023

Germany-based pharmaceutical giant Bayer (ETR: BAYN) has entered its fourth phase of partnership with the...

Company Drug

Transcenta Holding Ltd Secures Global Clinical Trial Approvals for Osemitamab in Gastric Cancer

Fineline Cube Jul 11, 2023

China-based Transcenta Holding Ltd has reported receiving clinical trial approvals from China’s Center for Drug...

Company

Pentax Medical to Establish Endoscope Manufacturing and R&D Site in Shanghai

Fineline Cube Jul 11, 2023

Japan-based Pentax Medical, a division of the Hoya Group specializing in endoscopic products, has announced...

Company Deals

Sinopep-Allsino Bio Pharmaceutical Cuts Fundraising Target to RMB434 Million via Convertible Bonds”

Fineline Cube Jul 10, 2023

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd has revised its proposal...

Company Drug

Shanghai BDgene Technology Receives US FDA Approval for HSV-1 Stromal Keratitis Gene Therapy

Fineline Cube Jul 10, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced receiving approval from the US...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Accepted for US FDA Review in IDE Process

Fineline Cube Jul 10, 2023

Ningbo-based structural heart disease intervention device manufacturer, Jenscare Scientific Co., Ltd (HKG: 9877), has announced...

Company Medical Device

Broncus Medical Inc. Launches First Regulatory Clinical Study for Targeted Lung Denervation System

Fineline Cube Jul 10, 2023

China-based Broncus Medical Inc., (HKG: 2216), a provider of precision intervention solutions focused on lung...

Company Deals Digital

Hainan Boao Lecheng Partners with Medlive for Medical Tourism and Online Doctor Education

Fineline Cube Jul 10, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a strategic partnership...

Company Drug

HutchMed Ltd Initiates Phase I Clinical Study for SHP2 Inhibitor HMPL-415 in Solid Tumors

Fineline Cube Jul 10, 2023

China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of a Phase I...

Company

GenScript Biotech Expands cGMP Manufacturing for Gene and Cell Therapy in Zhenjiang Facility

Fineline Cube Jul 10, 2023

China-based GenScript Biotech Corporation (HKG: 1548) has announced the expansion of its current Good Manufacturing...

Policy / Regulatory

China’s NAFR Enhances Tax Benefits for Private Health Insurance Purchases

Fineline Cube Jul 7, 2023

The National Administration of Financial Regulation (NAFR) in China has issued a Notification indicating that...

Company Deals

Jacobio Pharma Secures RMB 150 Million Investment to Advance Pipeline Programs

Fineline Cube Jul 7, 2023

China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in...

Company Medical Device

Genesis MedTech Secures Chinese Market Approval for ArtiSential Laparoscopic Surgical Device

Fineline Cube Jul 7, 2023

Singapore-based Genesis MedTech has announced that it has received market approval in China for its...

Company Drug

Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval

Fineline Cube Jul 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study

Fineline Cube Jul 7, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...

Company Deals

C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development

Fineline Cube Jul 7, 2023

China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint...

Company Deals

ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion

Fineline Cube Jul 7, 2023

China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to...

Company Medical Device

Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China

Fineline Cube Jul 7, 2023

Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced...

Posts pagination

1 … 473 474 475 … 634

Recent updates

  • Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
  • Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing
  • CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces
  • Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
  • APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.